お知らせ (information)


I am in the hospital for the treatment of cancer.

It will resume this blog little by little.



お知らせ (information)


お知らせ (information)

The near future, we will restart the blog.

お知らせ (information)

お知らせ (information)

It is in the hospital for the treatment of cancer.

Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版)No.25

Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版) No.25

Flags 【海外:overseas】
17 studies found for: cancer | received from 04/22/2016 to 04/22/2016

1 Recruiting
Fusion Guided Focal Laser Ablation of Prostate Cancer
Conditions: Prostate Cancer; Prostate Neoplasms
Intervention: Device: 1.2.Laser Ablation Device
Sponsor:National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:NCT02759744

2 Not yet recruiting
Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care
Conditions: Neoplasms; HIV; Healthcare Disparity
Intervention: Other: Potlako intervention
Sponsor:Harvard School of Public Health
ClinicalTrials.gov Identifier:NCT02752061

3 Not yet recruiting
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Condition: Urinary Bladder Neoplasms
Intervention: Procedure: Cryoablation
Sponsor:Huashan Hospital
ClinicalTrials.gov Identifier:NCT02760953

4 Not yet recruiting
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Anetumab ravtansine (BAY94-9343); Drug: Pegylated Liposomal Doxorubicin
ClinicalTrials.gov Identifier:NCT02751918

5 Not yet recruiting
Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
Condition: Breast Cancer
Intervention: Procedure: Axillary Lymph Node Sampling Clip
Sponsor:Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:NCT02752009

6 Not yet recruiting
A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Conventional radiotherapy; Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy
Sponsor:Lawson Health Research Institute
ClinicalTrials.gov Identifier:NCT02752126

7 Recruiting
Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy
Condition: Breast Cancer
Interventions: Behavioral: qualitative interviews with patients; Behavioral: questionnaires
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02753673

8 Not yet recruiting
A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers
Condition: Malignant Solid Tumor
Interventions: Biological: BMS-986179; Biological: Nivolumab
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02754141

9 Completed
Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer
Condition: Breast Cancer
Interventions: Behavioral: Prospective Surveillance Group; Behavioral: Education Group
Sponsor:University of British Columbia
ClinicalTrials.gov Identifier:NCT02754427

10 Completed
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Condition: Brain Neoplasm
Intervention: Biological: Gliolan
Sponsor:medac GmbH
ClinicalTrials.gov Identifier:NCT02755142

11 Not yet recruiting
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Microgynon; Drug: Nintedanib
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751385

12 Not yet recruiting
Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas
Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC)
Interventions: Drug: Birinapant; Drug: Paclitaxel; Drug: Carboplatin
Sponsor:Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:NCT02756130

13 Recruiting
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Condition: Cancer
Intervention: Drug: ARGX-110
Sponsor:arGEN-X BVBA
ClinicalTrials.gov Identifier:NCT02759250

14 Not yet recruiting
Real World Data on Gi(l)Otrif® Dose Adjustment
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gi(l)otrif®
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751879

15 Recruiting
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Procedure: Haploidentical Stem Cell Transplantation
Sponsor:Leonardo Javier Arcuri
ClinicalTrials.gov Identifier:NCT02759822

16 Not yet recruiting
A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions: Drug: ASP2215; Drug: Azacitidine
Sponsor:Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier:NCT02752035

17 Not yet recruiting
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat; Drug: pembrolizumab + placebo
Sponsor:Incyte Corporation
ClinicalTrials.gov Identifier:NCT02752074

◇EU, EMA, CHMP, Cancer Research UK, NICE◇
A JOURNEY THROUGH CANCER (05/05/2016 Cancer Research UK)
Everyone’s journey through cancer is different.Here we try to portray the experience through the words of those who know it best.This article has been drawn together from the memories, reflections and stories that patients have shared with us.By sharing these stories, we hope to show a little of what it can be like to go through cancer.

<Medical Journal & Other News>
【黒色腫/免疫チェックポイント療法の応答を予測できるタンパク質 Bim】JOURNAL:JCI Insight
Protein may predict response to immunotherapy in patients with metastatic melanoma (05/05/2016 EurekAlert!/MAYO CLINIC)
ROCHESTER, Minn. -- A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight."Immune checkpoint therapy with PD-1 blockade has emerged as an effective treatment for many advanced cancers," says the study's lead author, Roxana Dronca, M.D., an oncologist at Mayo Clinic. "However, only a fraction of patients achieve durable responses to immunotherapy and, to date, we have had no means of predicting which patients are most likely to benefit."

【肺がん/4つのPD-L1アッセイの分析】2016 Annual Meeting of the American Association for Cancer Research (AACR)
Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released (05/05/2016 EurekAlert!/INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER)
DENVER - A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in non-small cell lung cancer (NSCLC) clinical trials.

【神経障害性疼痛を低減】JOURNAL:Cell Reports
Research findings reveal potential to reverse cancer-related nerve pain (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.The study in rats showed transfer of a gene known as KCC2 into the spinal canal restored chloride levels gone awry after nerve injury. Results from the research at The University of Texas MD Anderson Cancer Center, were published in the May 5 online issue of Cell Reports.

【卵巣がん/治療標的 miR551b】JOURNAL:Cell Reports
Study points to therapeutic target for common and aggressive ovarian cancer (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.The study results, published in the May 5 online issue of Cell Reports, were reported by a team led by Gordon Mills, Ph.D., chair of Systems Biology at The University of Texas MD Anderson Cancer Center.

Study Suggests Medical Errors Now Third Leading Cause of Death in the U.S. (May 3, 2016  The Johns Hopkins University)
医療ミス、米国で死因3位 研究 (05/05/2016 AFPBB:日本語)
Analyzing medical death rate data over an eight-year period, Johns Hopkins patient safety experts have calculated that more than 250,000 deaths per year are due to medical error in the U.S. Their figure, published May 3 in The BMJ, surpasses the U.S. Centers for Disease Control and Prevention’s (CDC’s) third leading cause of death — respiratory disease, which kills close to 150,000 people per year.The Johns Hopkins team says the CDC’s way of collecting national health statistics fails to classify medical errors separately on the death certificate. The researchers are advocating for updated criteria for classifying deaths on death certificates.

Graphics 【日本国内:Japan】
<Press Release:日本国内>
抗がん剤の副作用 免疫力の低下や味覚障害など (05/06/2016 NEWSポストセブン)

横浜市 がん患者に生活支援 かつら購入など一部助成 (05/05/2016 タウンニュース)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆先見経済 (2016年5月号)/清話会/発売日:2016年5月5日/価格(税込):3,240円
・進化し続けるガン治療最前線 筑間晃比古



単行本: 310ページ
出版社: ポラーノ出版; 1版 (2016/4/27)
竹之内裕文, 浅原聡子 (編)
言語: 日本語
ISBN-10: 4908765006
ISBN-13: 978-4908765001
発売日: 2016/4/27
商品パッケージの寸法: 18.8 x 12.8 x 2.5 cm
keyword→grief care


<目次・table of contents>
序  対話する死生学  喪失とともに生きるために

1章  喪失とともに生きる人たちとの出会い グリーフカウンセリングの現場から
   ・コメント1  日本におけるグリーフケアカウンセラー 臨床心理学と日本的心性の狭間で
   ・コメント2  グリーフサポートと民俗

2章  こどものいのちを看取ること  小児救急の現場から
   ・コメント1  寄り添いの変容   一世紀を経た二つの手記より
   ・コメント2  こどもを看取る家族への看護

3章  生を享けること、失うこと  周産期医療の現場から
   ・コメント1  死産を経験した家族に対するサポート
   ・コメント2  幼い子を失った親の経験について

4章  老病死に向き合う人から学ぶ  終末期ケアの現場から
   ・コメント1  「自分を失うこと」とどう向き合うか
   ・コメント2  「ホスピタル」はいかに「病院」となったか

5章  ホームを失って生きる  路上生活者の語りから
   ・コメント1  「ホーム」の意味について考える
   ・コメント2  困窮する人を「助ける」ということ 私たちの「居場所」をめぐって

6章  がんが教えてくれたこと  患者・看護師としての体験から
   ・コメント1  がん闘病者・サバイバーの喪失体験と生
   ・コメント2  病とともに生きるということ

7章  自他の喪失を支えるつながり  グリーフから希望を
   ・コメント1  喪失から紡がれてゆくいのちのサポート
   ・コメント2  いのちの支え合いの場に立つ

終章  死とともに生きることを学ぶ  対話する死生学のために

<著者情報・author information>
竹之内 裕文(たけのうち ひろぶみ:TAKENOUCHI Hirobumi)
浅原 聡子(あさはら さとこ:ASAHARA Satoko)
 GCC 認定グリーフカウンセラー、グリーフカウンセリングivy代表

Links(Author's world・著作とその世界)
ポラーノ出版(polano publishing)

がん臨床試験(Clinical Trials - Japan/Malignancy 05/05/2015)神経芽腫 neuroblastoma

Cancer Clinical Trials Hub / Japan 
Types of Cancer, universities and medical institutions classification version(β版) 
がん臨床試験 がん腫・大学・医療機関別 分類版

◆最新臨床試験/悪性腫瘍(Latest Clinical Trials Registry/ Malignancy)◆
◆UMIN000022033 2016/05/05
Epidemiological studies of the incidence and mortality in after the end of the period of Neuroblastoma screening
・神経芽腫 neuroblastoma
・乳児期神経芽腫スクリーニング休止前後での神経芽腫の罹患と死亡の実態を明らかにすることである。 The purpose of this study is to clarify the incidence and mortality of neuroblastoma before and after the end of infancy neuroblastoma screening.
・0歳/years-old 以上/<=
・5歳/years-old 以下/>=
・男女両方/Male and Female
・家原 知子 Tomoko Iehara
・京都府立医科大学 Kyoto Prefectural University of Medicine
・京都府立医科大学 Kyoto Prefectural University of Medicine
・厚生労働省 Ministry of Health, Labour and Welfare

・その他関連情報/Other related information
厚労科研研究 Health and Labor Sciences Research Grant

がん臨床試験(Clinical Trials - Japan/Malignancy 05/04/2015)萎縮性胃炎 atrophic gastritis

Cancer Clinical Trials Hub / Japan 
Types of Cancer, universities and medical institutions classification version(β版) 
がん臨床試験 がん腫・大学・医療機関別 分類版

◆最新臨床試験/悪性腫瘍(Latest Clinical Trials Registry/ Malignancy)◆
◆UMIN000022204 2016/05/04
Detection of early gastric cancer using image-enhanced endoscopy
・萎縮性胃炎 atrophic gastritis
The aim of this study is to evaluate detection of early gastric cancer usig image-enhanced endoscopy for patients with atrophic gastritis
・20 歳/years-old 以上/<=
・男女両方/Male and Female
・今枝 博之 Hiroyuki Imaeda
・埼玉医科大学 Saitama Medical University
・埼玉医科大学 Saitama Medical University
・自己調達/Self funding

・その他関連情報/Other related information
First, conventional endoscopy
Second, BLI mode and LCI mode
Third, endoscopy using indigocarmine dye spraying
Finally, pathological diagnosis by biopsy specimen

Cancer Topics Index 05/05/2016(Daily Test version/ 日刊テスト版)No.24

Cancer Topics Index 05/05/2016(Daily Test version/ 日刊テスト版) No.24

Flags 【海外:overseas】
◇NCI (National Cancer Institute)◇
New on NCI’s Websites for May 2016 (May 2, 2016 by NCI Staff)
 Vaccine Therapy for Unresectable Chordoma
 Parents Who Have a Child with Cancer
 SEER Data, 1973-2013
Dividing Breast Cancer Cell
 NCI Cancer Close Up 2016 Collection Gallery 
 Kidney and Renal Pelvis Cancer | Did You Know?

 Melphalan (多発性骨髄腫、上皮性卵巣がん)
 Melphalan Hydrochloride (多発性骨髄腫)
 Defibrotide Sodium (幹細胞移植後の肝静脈閉塞性疾患)
 Venetoclax (慢性リンパ球性白血病[CLL])
 Learning to Relax
 ・Bladder and Other Urothelial Cancers Screening–Health Professional Version (PDQ®)
 ・Cancer Screening Overview–Health Professional Version (PDQ®)
 ・Childhood Acute Lymphoblastic Leukemia Treatment–Health Professional Version (PDQ®)
 ・Childhood Soft Tissue Sarcoma Treatment–Health Professional Version (PDQ®)
 Last Days of Life–Health Professional Version (PDQ®)
 ・Late Effects of Treatment for Childhood Cancer–Health Professional Version (PDQ®)
 ・Melanoma Treatment–Health Professional Version (PDQ®)
 ・Oral Cavity and Oropharyngeal Cancer Screening–Health Professional Version (PDQ®)
 ・Prostate Cancer, Nutrition, and Dietary Supplements–Health Professional Version (PDQ®)
 ・Topics in Integrative, Alternative, and Complementary Therapies–Health Professional Version (PDQ®)

6 studies found for: cancer | received from 04/21/2016 to 04/21/2016

1 Not yet recruiting
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Conditions: Breast Cancer; Early Stage; Triple Negative Breast Cancer
Interventions: Drug: Enzalutamide; Behavioral: assessment
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02750358

2 Completed
The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Behavioral: Active lifestyle programme
Sponsor:University of East Anglia
ClinicalTrials.gov Identifier:NCT02751892

3 Not yet recruiting
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
Sponsor:Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:NCT02749903

4 Not yet recruiting
Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients
Condition: Cancer
Interventions: Other: Reflexology; Other: Meditative Practices
Sponsor:Michigan State University
ClinicalTrials.gov Identifier:NCT02759146

5 Not yet recruiting
A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer
Condition: Advanced Cancer
Interventions: Biological: Nivolumab; Drug: Dasatinib; Biological: BMS-986016
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02750514

6 Not yet recruiting
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: Cladribine; Drug: Cytarabine; Biological: Filgrastim; Drug: Fludarabine Phosphate; Procedure: Hematopoietic Cell Transplantation; Drug: Melphalan; Drug: Methotrexate; Drug: Mitoxantrone Hydrochloride; Drug: Mycophenolate Mofetil; Other: Questionnaire Administration; Drug: Tacrolimus
Sponsor:University of Washington
ClinicalTrials.gov Identifier:NCT02756572

<Medical Journal & Other News>
【口腔がん/生存率の予測可能ながん遺伝子】JOURNAL:Otolaryngology-Head and Neck Surgery
Discovery of cancer gene may predict survival in patients with mouth cancers (05/04/2016 EurekAlert!/LOYOLA UNIVERSITY HEALTH SYSTEM)
MAYWOOD, IL - Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue.If the gene is expressed (turned on), patients are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

Findings light the way for new treatments in colitis, colon cancer (05/04/2016 EurekAlert!/OKLAHOMA MEDICAL RESEARCH FOUNDATION)
An Oklahoma Medical Research Foundation scientist has discovered that certain sugars produced by the body play an important role in the development of colitis and, ultimately, colon cancer. The new finding could potentially lead to therapies for ulcerative colitis, Crohn's disease and colon cancer.At OMRF, Lijun Xia, M.D., Ph.D., has spent two decades studying O-glycans, a form of sugar that the body produces and that comprises nearly 80 percent of a thick mucous layer inside the colon and the gastrointestinal tract.

【膵臓がん】JOURNAL:Diabetes, obesity & metabolism
Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.(PubMed/Diabetes Obes Metab. 2016 Mar)
糖尿病の人に頻発する膵臓がんは薬の副作用か? 18万人のデータ解析から (05/04/2016 MEDLEY:日本語)

Graphics 【日本国内:Japan】
がんの血液検査には「有害無益」な項目がある 「早期発見」の声に流されず、賢い選択を! 高野 利実 :虎の門病院臨床腫瘍科部長 (05/03/2016 東洋経済Online)

50歳以下の人には必要ない毎年の胃がん検診 内視鏡検査を選択肢に加え、50歳以上、2年に1回にするべき 多田 智裕・ただともひろ胃腸肛門科院長(05/02/2016 JBpress)

<新刊メタデータ:New Books>
監修:佐々木 寛/畠 榮, 則松 良明, 亀井 敏昭, 金城 満(編集)/大型本: 305ページ/出版社: 篠原出版新社 (2016/05)/ISBN-10: 4884123905/ISBN-13: 978-4884123901/¥10,800



大型本: 305ページ
出版社: 篠原出版新社 (2016/05)
佐々木 寛 (監修)畠 榮, 則松 良明, 亀井 敏昭, 金城 満 (編集)
ISBN-10: 4884123905
ISBN-13: 978-4884123901
keyword→Liquid based cytology 


<目次・table of contents>
第一部 液状化検体細胞診断の概要
 A-Ⅰ 液状化検体細胞診の歴史と役割
 A-Ⅱ 液状化検体細胞診の原理・検体処理・標本作製法ならびにその応用(シュアパス)
 A-Ⅱ 液状化検体細胞診の原理・検体処理・標本作製法ならびにその応用(ThinPrep)

第二部 従来法と液状化検体細胞診断の見方
 B-Ⅰ 婦人科
 B-Ⅱ 呼吸器
 B-Ⅲ 泌尿器
 B-Ⅳ 体腔液
 B-Ⅴ 甲状腺
 B-Ⅵ 乳腺
 B-Ⅶ 口腔
 B-Ⅷ 唾液腺
 B-Ⅸ 消化器
 B-Ⅹ 髄液・その他
 B-XI 悪性リンパ腫およびリンパ節病変


<著者情報・author information>
佐々木 寛 
千葉徳洲会病院婦人科部長/日本臨床細胞学会 理事長

Links(Author's world・著作とその世界)

がん臨床試験(Clinical Trials - Japan/Malignancy 05/02/2015)せん妄、嘔吐、吐き気 delirium, nausea and vomiting

Cancer Clinical Trials Hub / Japan 
Types of Cancer, universities and medical institutions classification version(β版) 
がん臨床試験 がん腫・大学・医療機関別 分類版

◆最新臨床試験/悪性腫瘍(Latest Clinical Trials Registry/ Malignancy)◆
◆UMIN000022172 2016/05/02
Efficacy and safety of olanzapine suppositories in terminally ill patients with delirium or nausea and vomiting
・せん妄、嘔吐、吐き気 delirium, nausea and vomiting
・該当せず/Not applicable
・参加者募集終了‐試験継続中/No longer recruiting
・内服困難な終末期患者においては、オランザピンの新しい剤形が必要である。坐剤は経口投与ができない場合、有用である。そこで、我々はオランザピン坐剤を作製し、せん妄、嘔吐、吐き気のある患者に投与し、その有効性と安全性を評価することを目的とする。 A new formulation of olanzapine available for terminally ill patients with oral feeding difficulties is needed. Rectal administration using suppositories is an alternative for patients for whom administration via the oral route is not feasible. So, we prepare olanzapine suppositories and evaluate the clinical efficacy and safety of olanzapine suppositories used to treat patients with delirium, vomiting, or nausea.
 内服困難な患者のせん妄、嘔吐、吐き気の治療にオランザピン坐剤が投与される。2.5 mg、5 mg、10 mgのオランザピン坐剤が1日1回投与される。
 Patients use olanzapine suppositories as a treatment for delirium or nausea and vomiting at the time of oral feeding difficulties. Patients are administered 2.5 mg, 5 mg, and 10 mg of olanzapine suppositories.
・20 歳/years-old 以上/<=
・適用なし/Not applicable
・男女両方/Male and Female
・宮澤 正幸 Masayuki Miyazawa
・湘南中央病院 Shonan Central Hospital
・湘南中央病院 Shonan Central Hospital
・自己調達/Self funding

Division of Practical Pharmacy, Keio University Faculty of Pharmacy